Single-center retrospective study of post-trastuzumab deruxtecan treatments in patient with HER2-positive metastatic breast cancer

Trastuzumab deruxtecan (T-DXd) can improve the prognosis of patients with HER2-positive metastatic breast cancer (mBC). However, data on treatments after T-DXd are lacking. A retrospective study at Aichi Cancer Center Hospital (Aichi, Japan) found that the median time to treatment failure with post-T-DXd treatment was only 3.5 months (95% CI 2.1-10.0), with no significant differences between HER2 tyrosine kinase inhibitor, other anti-HER2 treatments, or other treatments. The median overall survival was 14.9 months (95% CI 11.1-29.2). The authors conclude that further studies are required to establish the optimal post-D-Xd treatment for HER2-positive mBC.